• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    $CLXT
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBUS alert in real time by email

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor.

    "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said Nassim Usman, Ph.D., President & CEO of Totus Medicines. "With the promising results from our ongoing Phase 1 TOS-358 study and the recent strengthening of our leadership team - including the addition of Dr. Zelanna Goldberg as Chief Medical Officer - Totus is poised to emerge as a leader in the covalent small molecule space."

    "I am excited to join Totus Medicines and leverage my expertise in the biotech sector to support the advancement of our pipeline, which addresses critical unmet medical needs across multiple therapeutic targets," said Simon Harnest, MSc, BSc.

    Prior to joining Totus Medicines, Simon served as Chief Investment Officer at Metagenomi (NASDAQ:MGX), where he led successful private capital raises and the IPO process, contributing to over $1 billion in equity raised throughout his career with over 15 years of experience in the biotech sector. Prior to Metagenomi, Simon held the same role at Cellectis (NASDAQ:CLLS), where he directed the US IPO and capital markets strategy, as well as the spin-off and IPO of Calyxt (NASDAQ:CLXT) now Cibus (NASDAQ:CBUS). His background includes key positions at Trout Group and Trout Capital, specializing in investor relations for the life sciences industry. Simon holds a Master of Science in Public Health from the London School of Economics and a Bachelor of Science in Economics from the University of Westminster, London, UK.

    About Totus Medicines

    Totus Medicines is discovering and developing small molecule medicines using a novel DNA-encoded covalent library technology combined with artificial intelligence/machine learning (AI/ML). With the unprecedented ability to screen several hundred million drug candidates against multiple targets simultaneously, the company's novel platform can find drugs that are dramatically superior to molecules discovered through previous technologies, including drug candidates for currently undrugged and difficult to drug targets. Totus is developing TOS-358, a covalent PI3Kα inhibitor in a Phase 1 clinical trial and is developing potent and selective covalent inhibitors of several other targets internally and has a drug discovery partnership with Lilly.

    For more information, please visit totusmedicines.com and follow Totus on LinkedIn and Twitter/X.

    Contact:

    [email protected]

    External Contact:

    Brian Mullen

    LifeSci Advisors, LLC

    Managing Director

    [email protected]

    +1.203.461.1175 



    Primary Logo

    Get the next $CBUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBUS
    $CLLS
    $MGX
    $CLXT

    CompanyDatePrice TargetRatingAnalyst
    Cibus Inc.
    $CBUS
    7/29/2024$25.00Buy
    Alliance Global Partners
    Cibus Inc.
    $CBUS
    7/19/2024$22.00Buy
    Canaccord Genuity
    Metagenomi Inc.
    $MGX
    5/7/2024$10.00Buy
    H.C. Wainwright
    Metagenomi Inc.
    $MGX
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    Metagenomi Inc.
    $MGX
    3/5/2024Outperform
    TD Cowen
    Metagenomi Inc.
    $MGX
    3/5/2024$22.00Outperform
    BMO Capital Markets
    Metagenomi Inc.
    $MGX
    3/5/2024$16.00Overweight
    JP Morgan
    Metagenomi Inc.
    $MGX
    3/5/2024$23.00Buy
    Jefferies
    More analyst ratings

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Cibus Global with a new price target

      Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

      7/29/24 7:49:52 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Cibus Global with a new price target

      Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

      7/19/24 8:34:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on Metagenomi with a new price target

      H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

      5/7/24 6:26:47 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that the Ministry of Agriculture and Livestock in Ecuador has determined that Rice cultivars containing Cibus' herbicide tolerance Rice traits (HT1 and HT3) are equivalent to those developed through conventional breeding and subject to the same regulations as conventional seed in accordance with the provisions of the Organic Law of Agrobiodiversity, Seeds and Promotion of Sustainable Agriculture and its Regulations. The Rice trait products reviewed were developed utilizing Cibus' Rapi

      5/7/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      11/6/24 4:35:15 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

      SC 13D/A - Cellectis S.A. (0001627281) (Subject)

      5/21/24 4:19:05 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      5/10/24 6:40:45 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wapnick Pamela was granted 14,000 shares, increasing direct ownership by 23% to 73,684 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:31 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Thomas Brian C. was granted 32,000 shares, increasing direct ownership by 1% to 2,528,276 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:17 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Irish Jian was granted 23,000 shares, increasing direct ownership by 8% to 321,933 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:57:48 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metagenomi Announces New Appointment to its Board of Directors

      EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025. "We are excited to welcome Eric to our Board of Directors," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an in

      1/15/25 8:55:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

      UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

      11/4/24 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Financials

    Live finance-specific insights

    See more
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c

      4/25/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    $CLLS
    $MGX
    $CLXT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cibus Inc.

      10-Q - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:35:08 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:19:03 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      5/6/25 4:35:08 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care